Key result
Wearables show diagnostic utility for AF detection and HF prediction despite nighttime BP and algorithm limitations.
Why the study?
Wearable technologies have emerged as validated continuous cardiovascular risk monitoring tools, prompting a synthesis of evidence on their diagnostic performance and clinical utility.
Do wearable technologies improve the detection and monitoring of cardiovascular conditions compared to standard clinical monitoring?
Do wearable technologies improve the detection and monitoring of cardiovascular conditions compared to standard clinical monitoring?
Wearable devices offer clinically meaningful diagnostic utility for detecting atrial fibrillation and predicting heart failure hospitalization, though challenges remain with nighttime blood pressure accuracy and health equity.
Answers are grounded in this paper and cite their sources.
Supports selective wearable integration for AF detection and HF prediction; extends meta-analytic evidence while leaving BP accuracy and algorithm scope unresolved.
Background: Wearable technologies - including consumer smartwatches, adhesive ECG patches and photoplethysmography-based sensors - have emerged as validated tools for continuous cardiovascular risk monitoring outside clinical settings. Objective: This review synthesizes peer-reviewed clinical evidence from 2020 to 2025 on the diagnostic performance and utility of wearable devices in detecting atrial fibrillation (AF), ischemic stroke risk, arterial hypertension and heart failure (HF). Methods: A structured PubMed/MEDLINE, Scopus and Cochrane Library search was performed using Boolean MeSH combinations for wearable devices, arrhythmia, stroke, hypertension and heart failure, restricted to English-language RCTs, cohort studies, systematic reviews and meta-analyses from January 2020 to April 2025. Results: Pooled meta-analysis demonstrates Apple Watch AF sensitivity of 96.4% and specificity of 97.2% (Iqbal et al., 2025). The iRhythm Zio XT Patch achieves 2.58-fold greater AF detection than standard monitoring and anticoagulation initiation 15.3 percentage points higher in monitored patients (mSToPS). Post-stroke AF detection was 2.73-fold higher with patch monitoring than Holter (EPCAS trial). Cuffless BP wearables achieve acceptable daytime accuracy (mean SBP error -0.99 mmHg vs. ABPM) but subthreshold nighttime performance (4.48 mmHg). The LINK-HF study predicted HF hospitalization with 87% sensitivity up to six days in advance. Conclusions: Wearable devices demonstrate clinically meaningful diagnostic utility across multiple cardiovascular domains. Nighttime BP inaccuracy, algorithm scope limitations and insufficient equity data remain key barriers to universal clinical integration.
No takes yet. Share an insight, caveat, or question.
Ostruszka et al. (2026) conducted a review in Cardiovascular diseases (Atrial fibrillation, stroke, hypertension, heart failure). Wearable cardiovascular monitoring technologies vs. Standard clinical monitoring was evaluated. Wearable cardiovascular monitoring devices demonstrate clinically meaningful diagnostic utility for atrial fibrillation detection and heart failure prediction, though nighttime blood pressure inaccuracy and algorithm scope limitations remain barriers to universal integration.
Synapse has enriched 10 related papers. Consider them for comparative context: